Treatment of Helicobacter pylori: future therapeutic and prophylactic perspectives
A T R Axon
Centre for Digestive Diseases,
The General Infirmary At Leeds, Great George
Street, Leeds LS1 3EX, UK
| The first 150 words of the full text of this article appear below. |
| |
Summary |
|---|
Helicobacter is one of the most widespread, chronic infections in
the world and causes a serious disease with a significant mortality.
The organism is difficult to eradicate using antibiotic therapy and to
date no vaccine is available for use in humans. The most successful
treatments comprise acid suppression in combination with two
antibiotics and a series of seven day courses will reliably cure around
85% of infected individuals. Further modifications of these regimens
via the introduction of newer and more effective antibiotics and acid
suppressants may enable the treatment to be simplified, made more
effective and cause fewer side effects. However, the major challenge is
to develop a specific monotherapy targeted against Helicobacter
pylori. The H pylori genome has now been sequenced
and this provides an opportunity both to identify specific targets for
drug therapy, and to facilitate the identification and production of
antigens that may be helpful in
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
